List view / Grid view
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
20 November 2013 | By Daiichi Sankyo Europe
Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
19 November 2013 | By AstraZeneca
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre...
19 November 2013 | By AstraZeneca
The NDA filing was based on comprehensive data from the core Phase III KODIAC programme...
18 November 2013 | By Sanofi
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor...
18 November 2013 | By AbbVie
AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date...
BMG LABTECH, Inc. - the Microplate Reader Company - and InvivoSciences, Inc. - a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery - announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies.…
18 November 2013 | By Merck
Marketing authorization application also filed with the European Medicines Agency...
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
18 November 2013 | By AMSBIO
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.
18 November 2013 | By Abbott
Abbott was recognized by The Deal as the best all-around dealmaker in healthcare...
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
18 November 2013 | By Merck
“I am excited by the results seen for MK-3475 to date as a single agent..."
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
